The Center for Cancer & Blood Disorders
Current Clinical Trials as of July 18, 2011
We welcome your participation in a clinical trial for cancer research. If you would like more information on the clinical trials listed below, please call Joyce Wallace, Research Manager, at 817.759.7022 or send an email to jwallace@txcc.com.
| Diagnosis | Study Name | Brief Study Description |
| Triple Negative Breast | BRE 01-08 | Neoadjuvant weekly nab-paclitaxel (Abraxane) plus Carboplatin followed by Doxorubicin plus Cyclophosphamide with Bevacizumab added concurrently to chemo for palpable and operable triple negative breast cancer |
| Metastatic Breast | BRE 161 | Amrubicin as 2nd or 3rd Line Treatment for Patients with HER2 Negative Metastatic Breast Cancer |
| Colorectal | GI 134 | FOLFOXIRI plus Panitumumab as 1st Line Therapy for KRAS Wild-type Patients with Metastatic Colorectal Cancer with Liver Metastases Only |
| Diffuse Large B-cell Lymphoma | Novartis – RAD001N2301 | Randomized, CHOP-R +/- RAD 001 |
| Peripheral T-Cell Lymphoma | COMPLETE Registry | Primary objective is to describe, in detail, patterns of care for patients with peripheral T-cell lymphoma, by treatment setting. |
| Multiple Myeloma | Novartis CLBH589D2308 | Randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma |
| 1st Line NSCLC Poor Performance Status Patients |
SCRI LUN 196- TOPPS |
Randomized phase II trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in patients with Stage IIIB/IV NSCLC and ECOG performance status 2 |
| 1st Line NSCLC | Lilly H3E-US-S130 | Randomized, Open-Label study of Pemetrexed + Carboplatin in patients w/ Nonsquamous Histology |
| 1st Line NSCLC Squamous |
BiPar 20090321 (EFC11553) |
Randomized, Phase III Trial of Gemcitabine/Carboplatin with or without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Patients with Previously Untreated Stage IV Squamous NSCLC |
| Stage IV NSCLC | Lilly I4T-MC-JVBA | Randomized, double-blind, phase III study of Docetaxel and Ramucirumab vs. Docetaxel and placebo in the treatment of stage IV NSCLC following disease progression after one prior platinum-based therapy |
| Ovarian | GYN 19 | Randomized Study of Paclitaxel/Carboplatin with or without Sorafenib in the 1st Line Treatment of Patients with Stage III/IV Epithelial Ovarian Cancer |
| Prostate | BMS- CA184043 | Randomized, Double Blinded, Ipilimumab vs. Placebo post Radiotherapy |
| Unknown Primary | UNKPRI 20 | Chemotherapy Based on Molecular Profiling Diagnosis for Patients with Carcinoma of Unknown Primary Site |
 |
|